

 Madrigal in collaboration with

 RUTGERS HEALTH
Institute for Pharmaceutical
Industry Fellowships

Pharmaceutical Industry Fellowship Program 2027-2028

Table of Contents



About Madrigal

- Our Purpose
- Our Core Values
- Our Story
- Our Global Footprint
- Our Leadership



Medical Affairs Fellowship

- A Message from Leadership
- Leadership Team
- Program Goal and Program Overview
- Program Structure



Madrigal and the Community



Rutgers



Our Purpose

Leading the fight against **MASH.**

No family should have to go through the experience of watching a loved one struggle with decompensated cirrhosis or a liver transplant due to MASH. Our therapies are being developed to address MASH and its progression, with the goal of reducing the burden of advanced liver disease for patients and the healthcare system.

Every team member at Madrigal is dedicated to defeating MASH.

About Madrigal

A commercial-stage biopharmaceutical company dedicated to leading the fight against MASH, a serious liver disease



Home to Rezdiffra, the first approved therapy for MASH



Focused exclusively on addressing unmet needs in liver disease



Building the next generation of therapies to improve outcomes for patients



Rezdiffra[®]
resmetirom tablets
60mg • 80mg • 100mg



Our **focus on patients** is at the heart of everything we do.




Our **owner mindset** means we are accountable for our promises.



Our relentless **innovation** transforms hope into reality.



Our commitment to **collaboration** creates a brighter future for patients.



Every team member at Madrigal is dedicated to defeating MASH.

The Madrigal Story

2008
–2011

Dr. Becky Taub identifies a previously overlooked molecule – a THR- β agonist – and founds Madrigal to unlock its potential.



2016

Madrigal goes public on NASDAQ; raises funds to support Phase 2 trials.



2022
–2024

Landmark Phase 3 results lead to the first approved therapy for patients with MASH.

Bill Sibold joins Madrigal as CEO and Madrigal rapidly expands to support its first medication launch.



Stephen Harrison MD†

2025
–2026

The first MASH therapy is approved by the European Commission.

Madrigal expands its MASH pipeline with more than 10 new programs.



Growing Our Global Footprint

What began as a small team of researchers in Conshohocken, Pennsylvania, is now a fully integrated biopharmaceutical company with more than 1,000 employees in the United States and Europe.

U.S.



Europe



MASH is a Chronic and Progressive Liver Disease

MASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease

Normal Liver	MASL	MASH: Metabolic Dysfunction-Associated Steatohepatitis <i>MASH is the more advanced form of MASLD, which can progress to cirrhosis, liver failure, or result in premature death¹⁻⁵</i>		
	 Isolated steatosis (fat in $\geq 5\%$ of hepatocytes)	Early/Mild  F1: fibrosis stage 1	Moderate to Advanced  F2: fibrosis stage 2 F3: fibrosis stage 3	Cirrhosis  F4: fibrosis stage 4 - Cirrhosis further breaks down into compensated and decompensated

Hepatocytes, liver cells. **Steatosis**, excess fat in liver cells. **Steatohepatitis**, build up of excess fat in liver cells causing inflammation and damage.

1. Sheka AC, et al. *JAMA*. 2020;323(12):1175-83. 2. Alkhouri N, McCullough AJ. *Gastroenterol Hepatol* (N Y). 2012;8(10):661-8. 3. EASL-EASD-EASO. *J Hepatol*. 2016;64:1388-402. 4. Diehl AM, Day C. *NEJM*. 2017;377:3063-72. 5. Honda et al. *Int J Mol Sci*. 2020;21:4039.

Madrigal is Uniquely Positioned to Extend its Leadership in MASH

Our R&D strategy is to build the **industry-leading MASH pipeline** through targeted business development and internal innovation, **leveraging Rezdiffra as the foundational therapy**



Deliver transformational **outcomes** data, securing full approval from F2-F4c



Advance **combination therapies** anchored by Rezdiffra



Invest in **new modalities**, including ones that enable patient-specific care



Execute **disciplined, capital-efficient** clinical development

Why Madrigal – A Message From Leadership

Dear prospective fellow,

Thank you for your interest in the Rutgers Pharmaceutical Industry Fellowship (RPIF) Program at Madrigal. At Madrigal, our singular mission is to improve the lives of patients with MASH, a serious liver disease with significant unmet need. As the company behind the first FDA-approved therapy for MASH, we sit at a defining moment for this disease and the work our fellows will contribute to every day reflects that responsibility.

The Madrigal Medical Affairs Fellowship offers an opportunity to join our high-impact team during a pivotal period of growth and innovation. Our fellows will not be observers but integral members of our Medical Affairs team, contributing to meaningful scientific advancements while collaborating alongside experienced leaders committed to mentorship and professional development.

What sets this program apart is the depth of experience it offers. Our size and culture enable fellows to take on meaningful project ownership across functions, gaining visibility into the full scope of Medical Affairs at a growing commercial organization. The result is an immersive experience that builds the scientific, strategic, and leadership skills needed to become the next generation of Medical Affairs professionals.

We are excited to welcome individuals who are passionate about science, motivated to make an impact, and eager to grow alongside a team that is actively transforming the future of MASH care. If that sounds like you, we encourage you to explore our program and consider beginning your Medical Affairs journey with Madrigal and RPIF.

Sincerely,

The Madrigal Fellowship Leadership Team

Fellowship Program Overview

The Madrigal Medical Affairs Fellowship is a two-year postdoctoral program that prepares PharmD graduates for impactful careers in the pharmaceutical industry. Through structured, experiential learning, fellows gain hands-on experience across key Medical Affairs functions while developing therapeutic area expertise, core professional competencies, and confidence through meaningful project ownership and mentorship from experienced leaders. The result is an immersive training experience that will equip fellows to excel across diverse Medical Affairs roles.

Fellowship Structure – Year 1

The first year of the fellowship is designed to establish a strong foundation in Medical Affairs through a 12-month experience in two Scientific Communications functions, Global Medical Information and Scientific Training. Fellows will also gain disease state and product expertise. Working closely with dedicated preceptors, fellows will develop the scientific, training, operational, and communication skills that serve as the foundation for a successful career in Medical Affairs. Throughout the year, fellows will collaborate with colleagues across Medical Affairs, Regulatory, Legal, Commercial, Clinical Development, and other cross-functional teams while contributing to meaningful projects that support healthcare professionals and patients.

Expected Experiences Include:

1

Global Medical Information 6 months

- Gain exposure to Medical Information operations, including inquiry management, content management, and call center oversight.
- Develop and maintain medical information resources, including standard response documents, FAQs, and other scientific content that support consistent and accurate communication.
- Respond to unsolicited medical information requests by researching, evaluating, and communicating scientific and clinical data in a balanced, evidence-based, and compliant manner.
- Participate in medical and promotional review activities to gain an understanding of the review process and the collaborative roles of Medical Affairs, Regulatory, Legal, and Commercial.

2

Scientific Training 6 months

- Contribute to scientific education initiatives and collaborate with cross-functional partners to support the communication of emerging clinical data and medical insights.
- Assist with creating scientific training materials and educational resources for Medical Affairs colleagues.
- Develop and deliver medical education and onboarding programs to upskill the Medical Affairs organization and Madrigal broadly.
- Gain experience in adult learning principles, curriculum development, and training strategy.

Fellowship Structure – Year 2

Second year fellows will customize their experience by completing two six-month rotations aligned with their professional interests and career goals. Rotation opportunities include Scientific Content, Field Medical, and Medical Operations, allowing the fellow to gain deeper experience within selected areas of Medical Affairs while assuming greater ownership of projects and strategic initiatives. Throughout the year, fellows will continue to work closely with experienced Medical Affairs leaders and collaborate across functions to broaden their understanding of how Medical Affairs supports the product lifecycle. These focused experiences are designed to help fellows explore potential career paths, develop specialized expertise, and broaden their understanding of how Medical Affairs functions collaborate to support patients and healthcare professionals throughout the product lifecycle.

Scientific Content



- Develop scientific content to support medical education, field teams, and scientific exchange.
- Translate complex clinical data into clear, accurate, and impactful medical communications.
- Partner with cross-functional stakeholders to support strategic content planning and execution.

Field Medical



- Participate in core Medical Science Liaison (MSL) activities, including scientific exchange, healthcare professional engagement, and medical insight generation, under the guidance of experienced MSLs.
- Participate in field insight activities that help inform medical strategy and evidence generation.
- Develop an understanding of the strategic role of Field Medical in scientific exchange, evidence generation, and medical strategy throughout the product lifecycle.

Medical Operations



- Lead operational initiatives that enable efficient execution across Medical Affairs.
- Participate in cross-functional planning, project management and process improvement activities.
- Learn how Medical Operations supports strategic planning, execution, and organizational effectiveness across Medical Affairs.

Fellowship Leadership Team



Becky Lakata, RN, MSN

Fellowship Director – VP, Global Operations and Medical Excellence

Becky leads strategic medical operations and capability-building initiatives that enable operational excellence across Medical Affairs in support of Madrigal’s mission to advance therapies for MASH. A Registered Nurse with nearly 30 years of pharmaceutical industry experience, she has held leadership positions across Medical Affairs at Merck and Organon and the Medical Affairs Professional Society (MAPS). Becky is a dedicated leader and mentor in companies collaborating with RPIF, having helped develop fellowship programs across multiple organizations and mentored numerous Medical Affairs fellows throughout her career.

“

Together, we’re developing the next generation of Medical Affairs leaders who will transform scientific innovation into meaningful outcomes for patients.

”

Fellowship Leadership Team



Oksana Terleckyj, PharmD

Global Medical Information Preceptor – Director, Medical Information

Oksana is a Medical Information professional with 20+ years of experience across content development, call center management, promotional review, Medical Affairs strategy, and publication planning. She values being a resource for others and partnering across functions to address complex scientific questions and support informed healthcare decision-making. Oksana is passionate about mentorship and has served as a preceptor for the RPIF program as well as for pharmacy students.

“

Medical Information is the vital intersection of scientific expertise, effective communication, and cross-functional collaboration, leading to a meaningful impact on patient care.

”

Fellowship Leadership Team



Nisha Patel, PharmD

Scientific Training Preceptor – Director, Global Scientific Training

Nisha is the Global Scientific Training Director, leading the learning and development strategy for Global Medical Affairs to advance scientific excellence across the organization.

With more than 20 years of experience in the pharmaceutical and healthcare industries, Nisha brings expertise spanning Medical Affairs, Scientific Communications, Clinical Operations, and Commercial Strategy. A pharmacist by training, she began her career in clinical practice, where she developed a passion for translating complex scientific information into meaningful insights for patients and healthcare professionals. Nisha is dedicated to advancing scientific capability through innovative education and is passionate about mentoring and developing the next generation of healthcare and medical affairs professionals.

“

Education equals empowerment – whether you are a patient, caregiver, HCP, or a student – the more you can learn the better decisions you can make for yourself.

”

Fellowship Leadership Team



Beth Kamp, PharmD

Scientific Content Preceptor – Senior Director, Global Scientific Content

Beth leads our Global Scientific Content team which is entrusted with delivering high-quality, impactful scientific content that supports both internal and external stakeholders and enables effective scientific exchange and communication. With nearly 30 years working in both pharmaceutical companies and medical communication agencies, she has a unique perspective on shaping global scientific content strategy and execution. Beth is committed to mentoring fellows and enjoys helping them build confidence and strengthen their scientific communication skills.

“

Pharmacists are trained to make complex clinical information clear and meaningful for patients. That same skill translates naturally to scientific communications where clarity, accuracy, and impact are essential.

”

Fellowship Leadership Team



Travis Fisher, PharmD

Field Medical Preceptor – Executive Director, Field Medical

Travis leads a specialty-focused field medical organization that advances scientific engagement and strategic partnerships with thought leaders in support of Madrigal’s mission to “Lead the fight against MASH.” A Doctor of Pharmacy with more than 25 years of pharmaceutical industry experience, he has broad experience across medical affairs, regulatory affairs and commercial marketing, including medical leadership roles at Novo Nordisk and Procter & Gamble. Travis is passionate about developing future industry leaders and mentoring students and early-career professionals.

“

Be curious, embrace new opportunities, and don't be afraid to follow the path that excites you most—it may lead to a career you never imagined.

”

Fellowship Leadership Team



Karthik Chandrasekar, PharmD

Medical Operations Preceptor – Director, Medical Operations and Excellence

Karthik leads strategic initiatives to advance operational excellence and organizational capabilities across Global Medical Affairs. Prior to Madrigal, Karthik spent over six years in life sciences management consulting, advising pharmaceutical and biotechnology organizations on corporate strategy, commercialization, and business operations. He is passionate about developing future industry leaders and brings additional perspectives from evaluating emerging healthcare innovations and mentoring students and early-career professionals.

“

*Operational excellence enables great the science at Madrigal to reach patients.
I look forward to helping fellows understand how strategy, collaboration, and execution
come together to drive meaningful impact across Medical Affairs.*

”

Madrigal is Committed to Supporting the MASH Community



Community Screening and Education Fund

Madrigal has launched a **\$1,000,000** fund to support patient advocacy-led community screening and MASH disease education events across the U.S.



Stephen A. Harrison Patient Advocacy Fellowship

Madrigal is the founding sponsor of the Fatty Liver Foundation's patient advocacy scholarship honoring the legacy of Dr. Stephen Harrison.

The inaugural class of 20 scholars is already making an impact in the community.



Global Liver Institute Advanced Advocacy Academy

Madrigal is a multi-year supporter of the Advanced Advocacy Academy, a training program that helps emerging patient leaders engage with policymakers, journalists, regulators and drug developers.

Madrigal in the Community





Rutgers Pharmaceutical Industry Fellowship (RPIF) Program

Ernest Mario School of Pharmacy (EMSOP)

Rutgers, The State University of New Jersey

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of EMSOP, Dr. Carolyn Seyss, the Executive Director for the Institute for Pharmaceutical Industry Fellowships, and is supported by a team of RPIF alumni experienced in the pharmaceutical industry.



**Joseph A. Barone,
PharmD, FCCP**
*Dean and Distinguished
Professor*



**Carolyn Seyss,
PharmD, RUCIF**
*Fellowship
Executive Director*



**Joseph Fulginiti,
PharmD, MBA, RUCIF**
RPIF Associate



**Erica Dankiewicz,
PharmD, RUCIF**
RPIF Consultant



**Patrick Park,
PharmD, MBA, RUCIF**
RPIF Consultant

Program History

1984

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 26 companies within the pharmaceutical and biopharmaceutical industry with almost 300 Fellows.

2002

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Create the Fellowship structure, providing strategic leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

2018

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**.

Well over 1,900 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

RPIF FOSTERS the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through:

F	Family of Leading Companies Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.
O	Outstanding Alumni Track Record Well over 1,900 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
S	Strong Network Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
T	Trusted and Proven Since 1984 The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry, developing foundations for future leaders.
E	Enhanced Career Development Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
R	Rigorous Academic Component Rutgers affiliation provides academic and professional development opportunities.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

Application Process and Eligibility Requirements

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

HOW TO APPLY:

The RPIF Program is highly competitive. **Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.**

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **Wednesday, October 14, 2026** by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:

SUBMIT BY:

Application with short-answer questions	Tuesday, October 20th
Letter of Intent (LOI)	Tuesday, October 20th
Curriculum Vitae (CV)	Tuesday, October 20th
Letters of Recommendation (LORs)	Tuesday, December 1st

ADDRESS LOI AND LORs TO:

Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020





"My experience as an RPIF Fellow has been one of the most meaningful and transformative parts of my professional journey, providing countless opportunities for growth while reinforcing the importance of giving back to the Ernest Mario School of Pharmacy community. I am grateful to draw upon my nontraditional experiences prior to pharmacy school to mentor, support, and advocate for our RPIF Fellows, encouraging them to embrace their own unique backgrounds as strengths in their professional careers. Investing in their professional and personal development is especially rewarding because today's Fellows will become tomorrow's leaders, advancing innovations that improve the lives of patients and strengthen the communities we serve."

John (Eun Sik) Cho, PharmD
Global GMP QA Strategy



"It is hard to put into words how much this fellowship has meant to me in just my first year. RPIF has challenged me to grow, think differently, and embrace opportunities I never imagined having this early in my career. Knowing that my work has the potential to impact patient care on a global scale has been incredibly rewarding, and I am excited to see how RPIF continues to shape my career and growth as a leader. I encourage future fellows to take advantage of everything the program has to offer because the experiences you gain and the relationships you build will shape your future."

Hillary Anne Reeves, PharmD
Late-Stage Clinical Development



"I am incredibly grateful for the personal and professional growth I have experienced as a Rutgers Fellow. Through RPIF and my partner company, I have been able to learn from inspiring mentors, collaborate with talented peers, and pursue opportunities that have accelerated my development. Being surrounded by such a supportive fellowship community has made this experience especially meaningful and has helped me feel prepared and excited for the future!"

Brynn Gilbert, PharmD
Medical Communications

AIFA
Alliance of Industry Fellowship Associates

**Aligned First Offer Date
December 11, 2026**

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this AIFA-aligned offer date. Candidates should feel free to request an extension for any earlier offer to allow them to consider their options.